NANOCARRIER BASED INTRALYMPHATIC IMAGING AND THERAPY FOR MELANOMA

基于纳米载体的淋巴内成像和黑色素瘤治疗

• 批准号: 7959404
• 负责人: Mark Steven Cohen
• 金额: $ 14.1万
• 依托单位: UNIVERSITY OF KANSAS LAWRENCE
• 依托单位国家: 美国
• 财政年份: 2009
• 资助国家: 美国
• 起止时间: 2009-03-01 至 2010-02-28
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/7959404
• 关键词: Cancer Center; Computer Retrieval of Information on Scientific Projects Database; Contrast Media; Cutaneous Melanoma; Disease; Drops; Drug Delivery Systems; Funding; Gadolinium; Goals; Grant; Hyaluronic Acid; Image; Institution; Lymphatic; Magnetic Resonance Imaging; Melphalan; Methods; Modality; Morbidity - disease rate; Nanotechnology; Neoplasm Metastasis; Organ; Pharmaceutical Preparations; Research; Research Personnel; Resources; Site; Skin; Skin Cancer; Source; Staging; Survival Rate; System; Therapeutic; Toxic effect; United States National Institutes of Health; base; cancer imaging; falls; improved; lymph nodes; melanoma; nanocarrier; novel; tumor

This subproject is one of many research subprojects utilizing the resources provided by a Center grant funded by NIH/NCRR. The subproject and investigator (PI) may have received primary funding from another NIH source, and thus could be represented in other CRISP entries. The institution listed is for the Center, which is not necessarily the institution for the investigator. The rate of melanoma skin cancer is increasing yearly with 60000 new cases in 2007 in the US alone. Melanoma is highly curable if treated before it has spread from the primary site on the skin, but 5-year survival rates drop to only 29% once disease has spread to lymph nodes and fall even lower (down to 7%) if tumors metastasize to major organs. The goal of this proposal is to devetop and optimize a new drug-delivery and imaging platform for melanoma staging and treatment. Since melanomas naturally spread initially through local lymphatic channels and lymph nodes, this delivery and imaging system will specifically target the lymphatics. Using nanotechnology, hyaluronic acid, a compound naturally found in the body, is combined with drugs like melphalan normally used in regional therapy for melanoma, and delivered through the lymphatics. By lymphatic drug-delivery, the tumor is treated in a targeted manner, decreasing the amount of drug absorbed systemically which should result in a lower toxicity profile than the way it is currently administered. In addition to treating early melanoma through the lymphatics, this nanocarrier can be combined with gadolinium and imaged by MRI. Utilizing intralyrnphatic delivery for a contrast agent, this proposal will also explore novel ways to image lymphatically spread tumors such as melanoma. If successful, this research will result in an improved method for treating and imaging early to intermediate stage melanoma avoiding the morbidity of current treatment modalities and advancing the field of cancer imaging and therapeutics for lymphatically spread tumors.

该副本是利用众多研究子项目之一 由NIH/NCRR资助的中心赠款提供的资源。子弹和 调查员（PI）可能已经从其他NIH来源获得了主要资金， 因此可以在其他清晰的条目中代表。列出的机构是 对于中心，这不一定是调查员的机构。 仅在2007年，在美国，黑色素瘤皮肤癌的发生率每年增加，每年有60000例新病例。如果在皮肤上的主要部位传播之前对黑色素瘤进行治疗，那么黑色素瘤就可以治愈，但是一旦疾病扩散到淋巴结，5年的存活率下降到只有29％，并且如果肿瘤转移到主要器官，则降低（降至7％）。该提案的目的是Devetop并优化用于黑色素瘤分期和治疗的新药物递送和成像平台。由于黑色素瘤自然 最初通过局部淋巴通道和淋巴结传播，该输送和成像系统将特别针对淋巴管。使用纳米技术，透明质酸是体内自然发现的一种化合物，与Melphalan这样的药物结合 通常用于黑色素瘤的区域治疗，并通过淋巴管递送。 通过淋巴药的递送，以靶向方式治疗肿瘤，从系统地减少吸收的药物量，这应该导致毒性概况低于当前使用的毒性。除了通过淋巴机治疗早期黑色素瘤外，该纳米载体还可以与gadolinium结合并由MRI成像。该提案利用对比剂的跨斜向递送，还将探索新颖的淋巴样肿瘤（例如黑色素瘤）的方法。如果成功，这项研究将导致一种改进的方法来治疗和成像早期到中级黑色素瘤，以避免当前治疗方式的发病率，并推动癌症成像和治疗剂的领域，以扩散肿瘤。